Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted

Description

Objective . We aimed to identify mortality trends associated with COVID-19 deaths in Peru during April through November 2020, when mass treatments with ivermectin (IVM), a drug of Nobel Prize-honored distinction, were autonomously deployed at different times and to different extents in Peru's 25 states under a national policy that authorized these treatments. Design . Ecological study of publicly available data. Excess deaths were analyzed state by state. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations, seropositivity rates and other auxiliary data were also examined. Primary outcome . Reductions in excess deaths, state by state, as compared with extent and time period of IVM treatments. Participants . The study population was restricted to ages ≥ 60 to eliminate confounding effects of changing age distributions of COVID-19 incidence. Results . The 25 states of Peru were grouped by extent of IVM distributions: maximal (mass IVM distributions through operation MOT , a broadside effort led by the army); medium (locally managed IVM distributions); and minimal (restrictive policies in one state, Lima). The mean…

Description from Zenodo, shortened.

Files (4)

• XLSXReadme_SINADEF_frozen_datasets_used_for_Peru_excess_deaths_analyses__all_fields.xlsx15 kB
• PDFLinks_to_the_key_Peruvian_national_databases_used__with_a_database_map__for_Ivermectin_for_COVID-19_in_Peru.pdf157 kB
• CSVSINADEF_DATOS_ABIERTOS_23022021.csv40 MB
• CSVSINADEF_DATOS_ABIERTOS_13122020.csv36 MB

DataHunter does not store or host these files: every link leads to the original source. Check the license there before using the data.